July 27, 2012 — C. R. Bard Inc. announced that its Lutonix technology center has completed patient enrollment into its ...
Drug-Eluting Balloons
This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.
July 9, 2012 — Cardionovum GmbH announced it has initiated in vivo testing of its second drug-eluting balloon (DEB) Rest ...
July 09, 2012
June 13, 2012 — Physicians presented at EuroPCR 2012 the results of two multicenter, randomized controlled trials, the ...
June 13, 2012
April 17, 2012 –– Expanding its commitment to developing innovative treatments for cardiovascular disease and the ...
April 17, 2012
March 20, 2012 - MarBlue Medical announced the global product launch of its CE-marked drug-eluting balloon (DEB) Protege ...
March 20, 2012
January 25, 2012 — Physicians at University Hospitals (UH) Case Medical Center enrolled their first patient in LEVANT 2 ...
January 25, 2012
January 6, 2012 - C. R. Bard recently announced it acquired drug-eluting balloon maker Lutonix Inc. for $225 million ...
January 06, 2012December 28, 2011 – Good Samaritan Hospital in Los Angeles is participating in the Levant 2 clinical trial to ...
December 28, 2011
November 14, 2011 — A clinical trial of patients with restenosis in drug-eluting stents (DES) in native coronary ...
November 14, 2011
November 14, 2011 – Medrad Inc. announced that five-year data from the THUNDER trial [1] demonstrated a 59 percent ...
November 14, 2011September 15, 2011 – The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first ...
September 16, 2011
September 15, 2011 — Very positive results were reported in the first account of a clinical study evaluating the ...
September 15, 2011
July 26, 2011 – The first patient has been enrolled in the LEVANT 2 clinical trial, a global, multi-center, randomized ...
July 26, 2011May 17, 2011 - Medrad Inc., a business of Bayer HealthCare, today announced it has received CE Mark for its Cotavance ...
May 18, 2011
November 17, 2010 – A drug-eluting balloon (DEB) and a coronary stent have received CE mark approval in Europe ...
November 17, 2010© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now